Modern Chinese Medicine Group Co., Ltd. (HKG:1643)
Hong Kong · Delayed Price · Currency is HKD 2.470
+0.180 (7.86%)
Jun 1, 2026, 4:08 PM HKT
HKG:1643 Revenue
In the year 2025, Modern Chinese Medicine Group had annual revenue of 145.17M CNY, down -32.18%. Modern Chinese Medicine Group had revenue of 80.42M in the half year ending December 31, 2025, a decrease of -50.96%.
Revenue
145.17M CNY
Revenue Growth
-32.18%
P/S Ratio
11.01
Revenue / Employee
768.12K CNY
Employees
189
Market Cap
1.78B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 145.17M | -68.89M | -32.18% |
| Dec 31, 2024 | 214.07M | -130.01M | -37.78% |
| Dec 31, 2023 | 344.08M | -55.58M | -13.91% |
| Dec 31, 2022 | 399.66M | 38.96M | 10.80% |
| Dec 31, 2021 | 360.70M | 52.00M | 16.85% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 44.73B |
| WuXi Biologics | 24.25B |
| Hansoh Pharmaceutical Group Company | 16.72B |
| Innovent Biologics | 14.51B |
| Essex Bio-Technology | 1.81B |
| Dawnrays Pharmaceutical (Holdings) | 1.37B |
| PW Medtech Group | 916.40M |
| Mabpharm | 718.98M |